ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NVAX Novavax Inc

15.2308
-0.4692 (-2.99%)
After Hours
Last Updated: 23:46:57
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.4692 -2.99% 15.2308 15.15 15.30 16.21 14.84 16.16 17,728,541 23:46:57

Novavax to Participate in BofA Securities 2024 Health Care Conference

13/05/2024 9:02pm

PR Newswire (US)


Novavax (NASDAQ:NVAX)
Historical Stock Chart


From Apr 2024 to May 2024

Click Here for more Novavax Charts.

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Conference Details:



Fireside Chat


Date:

Wednesday, May 15, 2024

Time:

3:00 – 3:30 p.m. Pacific Daylight Time (PDT)

Location:

Encore Hotel in Las Vegas, NV

Moderator:

Alec Stranahan, PhD, Equity Research – U.S. Biopharma

Novavax participant:

John C. Jacobs, President and Chief Executive Officer



Conference


Event:

Investor Meetings

Date:

Wednesday, May 15, 2024

Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html

SOURCE Novavax, Inc.

Copyright 2024 PR Newswire

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart